Introduction
============

The contemporary approach to a patient with ischemic-type chest pain is to categorize them as experiencing an acute coronary syndrome (ACS) with or without ST segment elevation. The assessment of the initial 12-lead electrocardiogram (ECG) is therefore of critical importance as the management strategy is different for each group ([@b2]; [@b11]). Prompt identification of patients with acute ST segment elevation myocardial infarction (STEMI) is vital if patients are to benefit from contemporary management strategies. Over the last 3 decades, major advances in our understanding of the pathophysiological processes responsible for STEMI and its sequelae have allowed development of pharmacological therapies to target these different processes. Numerous large well designed randomized controlled trials have guided determination of ever superior management strategies and their increasing utilization has been associated with a corresponding steady decline in death from acute myocardial infarction (MI) ([@b23]).

Pathophysiology of STEMI
========================

Complex inflammatory mechanisms are now known to participate in all stages of coronary artery disease, from the initial development of the fatty streak, through progression to advanced atherosclerotic lesions causing angina pectoris, to plaque disruption and thrombus formation. Plaques vulnerable to disruption and rupture are frequently non-obstructive but have a large lipid-rich core and a high macrophage content leading to thinning of the fibrous cap ([@b34]; [@b16]; [@b39]). Plaque rupture, which typically occurs at the edge or shoulder region, exposes the lipid core, leading to platelet adhesion and aggregation, activation of the coagulation cascade, and formation of a platelet rich thrombus. A key step in this process is activation of prothrombin to thrombin (factor IIa) which promotes the formation of fibrin, the protein which acts as a scaffold in stable thrombus. The fate of the thrombus then ranges from simple incorporation into the plaque, through subtotal artery occlusion, to fully occlusive thrombus formation ([@b14]), the latter typically presenting clinically as STEMI ([@b17]).

Reperfusion strategies for STEMI
================================

Where possible, the immediate treatment goal in STEMI is to disperse the thrombus thereby restoring coronary blood flow to the culprit artery ([@b2]) in order to limit infarct size, to preserve left ventricular function, and ultimately, to reduce mortality.

Two decades on from the landmark GISSI trial with streptokinase, fibrinolytic therapy remains the most widely used reperfusion strategy ([@b26]). Second and third generation fibrinolytic agents interact directly with clot-bound plasminogen improving fibrin selectivity and achieve higher rates of early patency although this has translated at most into only a small further reduction in mortality. More important than the fibrinolytic agent used is the time delay from symptom onset to drug administration ([@b20]; [@b10]) and hence the value of third generation bolus agents which help facilitate pre-hospital use.

Catheter based reperfusion with primary percutaneous coronary intervention (PCI) where available within a reasonable timeframe, may lead to even better reduction in cardiovascular events, except in patients who present very rapidly after symptom onset when both strategies appear to be equivalent ([@b30]; [@b41]). Primary PCI is associated with a reduced risk of bleeding complications, in particular intracranial hemorrhage ([@b30]) which typically occurs in approximately 1% of patients treated with a fibrinolytic based regimen. Trials have shown that the adjuvant anticoagulant dose may play a significant role in the risk of intracranial hemorrhage ([@b22]).

Adjuvant antiplatelet therapy
=============================

The importance of adjuvant aspirin was established in ISIS-2 ([@b29]) and the value of concurrent clopidogrel in the more recent CLARITY and COMMIT trials ([@b12]; [@b37]). It is likely that their primary benefit is to reduce reocclusion following successful reperfusion ([@b38]). Initial trials of glycoprotein IIbIIIa receptor antagonists in combination with reduced dose fibrinolytic appeared promising, improving early patency and ST resolution ([@b5]). However the large GUSTO V trial found only a small efficacy advantage in selected subgroups which was offset by a significant increase in bleeding risk ([@b27]).

Adjuvant anticoagulant therapy
==============================

While adjuvant anticoagulant therapy may give a small improvement in patency ([@b36]), like antiplatelet therapy, its main role is in helping to maintain patency after successful reperfusion. Additional potential benefits include prevention of deep venous thrombosis, pulmonary embolism and left ventricular thrombus. Current therapy choices include conventional unfractionated heparin (UFH) and newer agents, in particular low molecular weight heparin (LMWH), factor Xa inhibitors and direct thrombin inhibitors. The mechanism of action of these agents is illustrated in [Figure 1](#fig1){ref-type="fig"}.

![Interaction of anti-thrombotic agents with coagulation cascade. UFH-antithrombin III complex has approximately equal inhibitory effects on factor Xa and IIa. LMWH-antithrombin III complex has greater relative specificity for factor Xa. Pentasaccharide-antithrombin III complex acts only on factor Xa.\
**Abbreviations:** UFH, unfractionated heparin; LMWH, low molecular weight heparin; DTI, direct thrombin inhibitors.](vhrm0402-305-01){#fig1}

The guidelines mandate the concomitant use of anti-coagulant treatment with either pharmacological or mechanical reperfusion ([@b2]). An area of controversy has existed regarding the need of otherwise for anticoagulation with streptokinase as the latter induces prolonged fibrin depletion. Two meta-analyses, both published in 1996, failed to show evidence of clear benefit with adjuvant UFH ([@b13]; [@b32]). However, more recent placebo controlled data have demonstrated benefit for use of concomitant LMWH ([@b40]; [@b50]) and factor Xa inhibition ([@b49]) with streptokinase. Of note there is a paucity of placebo-controlled evidence for use of adjuvant anticoagulation with the fibrin-specific agents, or indeed primary PCI, mainly because of a presumption that anticoagulation use in these settings is clearly indicated.

Unfractionated heparin
======================

Heparin is a heterogeneous mucopolysaccharide which interacts with antithrombin-III greatly increasing its inhibitory effects on thrombin ([@b28]). The heparin-antithrombin-III complex also has inhibitory effects on factor Xa and other clotting factors. Use of concurrent intravenous heparin has been shown to decrease early thrombin activity, improve culprit artery patency and reduce reocclusion, although the value of delayed subcutaneous (SC) heparin following fibrinolytic therapy is less clear ([@b43]; [@b32]; [@b24]). A recent meta-analysis failed to show a clear benefit for UFH compared to placebo ([@b19]). A major drawback with UFH is the significant variability in therapeutic response which occurs because of its heterogeneous composition and necessitates close monitoring of the activated partial thromboplastin time (aPTT). The typical regimen for use in STEMI is an initial bolus of 60 U/kg (max 4000 U) and continued as an infusion of 12 U/kg/hr (max 1000 U/hr) for 48 hours adjusted to achieve an aPTT of 50--70 seconds. It is notoriously difficult to achieve and maintain the aPTT within this target range, and under-treatment is a significant problem. In the TIMI 9B trial only approximately one third of patients had an aPTT within the target range at any given time, with between 25%--52% having sub-therapeutic levels ([@b6]). Ensuring that the aPTT does not rise above 70 seconds is of vital importance because, once exceeded, the absolute risk of intracranial hemorrhage rises in direct proportion to the aPTT ([@b25]). UFH can also give rise to an immunologically mediated thrombocytopenia known as heparin induced thrombocytopenia (HIT) which is rare but potentially life threatening. These drawbacks, together with the requirement for continuous intravenous (IV) administration, make UFH a less than ideal anticoagulant agent.

Low molecular weight heparin
============================

LMWHs are approximately one third of the molecular weight of UFH, conferring greater bioavailability following subcutaneous administration ([@b4]). Weight adjusted SC bolus dosing leads to stable and reliable anticoagulation without the need for monitoring, meaning they are much more convenient to administer in clinical practice. As well as improving bioavailability, once binding to antithrombin-III occurs, greater relative specificity for factor Xa is provided when compared to UFH, producing enhanced blockade of the coagulation cascade upstream of thrombin generation. The ratio of inhibition of factor Xa:IIa varies between agents (for enoxaparin the ratio is 3:1) ([@b7]). HIT is less common with LMWH compared to UFH ([@b46]), but it is important to remember that, because LMWHs are made by depolymerisation of UFH, they can still give rise to this condition.

Placebo controlled studies with LMWH have confirmed the importance of an adjuvant anticoagulant strategy. The AMI-SK study of 496 streptokinase treated MI patients showed that adjuvant enoxaparin compared with placebo improved early patency by 22%, improved early ST-segment resolution and was associated with a 36% reduction in the composite of death, reinfarction and recurrent angina ([@b40]). The CREATE trial compared the LMWH reviparin with placebo in 15570 patients with STEMI ([@b50]), of whom 73% received fibrinolytic therapy and 6.1% underwent primary PCI, the remainder being treated conservatively. Reviparin significantly reduced the composite endpoint of death, reinfarction and stroke although those receiving fibrinolytic therapy had an increased the risk of major bleeding including intracranial hemorrhage (0.4% vs 0.1% for reviparin and placebo groups respectively).

Enoxaparin has been extensively compared to UFH following fibrinolytic therapy for acute MI (see [Table 1](#tbl1){ref-type="table"}). Following early studies (Baird et al and HART II), the ASSENT-3 trial randomized over 6000 patients receiving tenecteplase to full-dose tenecteplase and enoxaparin, half-dose tenecteplase with weight-adjusted low-dose UFH and a 12-hour abciximab infusion, or full-dose tenecteplase with 48 hours UFH ([@b8]). Administration of enoxaparin with full dose tenecteplase led to significant reductions in 30-day mortality, in-hospital reinfarction and in-hospital recurrent ischemia compared with UFH, with no significant increase in overall bleeding.

###### 

Important randomized controlled trials comparing LMWH with UFH in patients treated with fibrinolytic therapy for STEMI

  Trial                                                                       Patients              LMWH regimen                                                                                                  UFH regimen                                                                     Outcomes
  --------------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baird et al[a](#tf1-1){ref-type="table-fn"}                                 300                   Enoxaparin 40 mg IV bolus then 40 mg SC 8 hourly for 4 days                                                   IV bolus, then infusion to maintain aPTT 2--2.5 × normal for 4 days             Significant reduction in death, non-fatal reinfarction or readmission with unstable angina at 90 days in favor of enoxaparin.No significant difference in major hemorrhage.
  HART II[b](#tf1-2){ref-type="table-fn"}                                     400                   Enoxaparin 30 mg IV bolus then 1 mg/kg SC 12 hourly for ≥72 hours                                             IV bolus, then infusion to maintain aPTT 2--2.5 × normal for ≥77 hours          Enoxaparin non-inferior to UFH.No significant difference in adverse events.
  ENTIRE-TIMI 23[c](#tf1-3){ref-type="table-fn"}                              483                   Enoxaparin 30 mg IV bolus then 1 mg/kg SC 12 hourly for 8 days or discharge                                   IV bolus, then infusion to maintain aPTT 1.5--2.5 × normal for ≥36 hours        No significant difference in TIMI 3 flow at 1 hour.Significant reduction in death/reinfarction at 30 days for enoxaparin compared with UFH.No significant difference in major bleeding.
  ASSENT-3[d](#tf1-4){ref-type="table-fn"},[e](#tf1-5){ref-type="table-fn"}   6095                  Enoxaparin 30 mg IV bolus then 1 mg/kg SC 12 hourly for 7 days or discharge (2040 patients)                   IV bolus, then infusion to maintain aPTT 50--70s for ≥48 hours(2038 patients)   Significant reductions in 30-day mortality, in-hospital reinfarction and in-hospital recurrent ischemia for enoxaparin compared with UFH.No significant increase in overall bleeding.
  ASSENT-3 PLUS[f](#tf1-6){ref-type="table-fn"}                               1639 (pre-hospital)   Enoxaparin 30 mg IV bolus then 1 mg/kg SC 12 hourly for 7 days or discharge                                   IV bolus, then infusion to maintain aPTT 50--70s for ≥48 hours                  Reduction in early ischemic events with enoxaparin.Excess intracranial hemorrhage in patients \>75 years.
  ExTRACT[g](#tf1-7){ref-type="table-fn"}                                     20475                 Enoxaparin 30 mg IV bolus then 1 mg/kg SC 12 hourly for 8 days or discharge[h](#tf1-8){ref-type="table-fn"}   IV bolus, then infusion to maintain aPTT 1.5--2 × normal for ≥48 hours          Significant reduction in death or re-infarction.Significant increase in major bleeding.No significant difference in intracranial hemorrhage.
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Third arm in this trial was half-dose tenecteplase with weight-adjusted low-dose UFH and a 12-hour abciximab infusion.

[@b45].

[@b1].

Regimen included a reduced dose in patients ≥75 years (no initial IV bolus, SC dose reduced to 0.75 mg/kg) and a reduced frequency (once a day) in patients with impaired renal function.

**Abbreviations:** LMWH, low molecular weight heparin; UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.

However, the ASSENT-3 PLUS study of over 1600 pre-hospital patients ([@b45]) showed an excess of intracranial hemorrhage with enoxaparin in patients \>75 years, suggesting that a dose reduction was needed in this age group. The pivotal 20475 patient ExTRACT-TIMI 25 study ([@b1]) thus compared UFH (standard bolus and 48 hour infusion) with a modified enoxaparin regimen -- standard 30 mg IV bolus then 1 mg/kg bd until hospital discharge, but reduced dose in patients ≥75 yrs (no initial IV bolus, SC dose reduced to 0.75 mg/kg) and a reduced frequency (once a day) in patients with impaired renal function. Median treatment duration with UFH was 2.0 days (interquartile range 2.0--2.2) and with enoxaparin was 7.0 days (interquartile range 4.5--7.5). Enoxaparin was associated with a 17% reduction in death or MI (9.9% vs 12%; p \< 0.001), excess major bleeding (2.1% vs 1.4%) but no excess of intra-cranial hemorrhage (0.8% vs 0.7%; p = 0.14) and overall net clinical benefit. Although it may be argued that ExTRACT was a comparison of treatment durations rather than drugs, even at 48 hours, the composite of death, MI and urgent revascularization was significantly reduced with enoxaparin treatment (6.1% vs 5.3%; p = 0.02). Based on ExTRACT trial data, the Food and Drug Administation have formally approved enoxaparin for use in ST elevation MI.

A planned substudy of the ExTRACT trial (ExTRACT-PCI) evaluated whether enoxaparin was superior to UFH in those STEMI patients (almost a quarter of the total study cohort) who received thrombolytic therapy and subsequently underwent PCI within 30 days ([@b21]). By 30 days, patients randomised to enoxaparin showed a 23% relative reduction in death or MI compared to UFH (10.7% vs. 13.8%; p = 0.001) without a significant difference in the risk of major bleeding. Almost one half of the patients in this substudy underwent PCI while still receiving blinded study drug. Again, for this cohort, a reduction in 30 day death or MI risk was seen in the enoxaparin group compared to the UFH group (13.0% vs 16.7%; p = 0.013) without an increased risk of major bleeding.

Pentasaccharides
================

Pentasaccharides are manufactured to have a chemical structure similar to the antithrombin-III binding domain (active site) of heparin. Binding of pentasaccharide to antithrombin-III induces conformational changes leading to selective and potent inhibition of factor Xa resulting in greatly reduced thrombin generation ([@b15]). Unlike UFH and LMWH there is no inhibitory effect on thrombin molecule itself. Pentasaccharides, such as fondaparinux, can therefore be considered as synthetic, highly selective, indirect inhibitors of factor Xa. Potential advantages of fondaparinux include 100% bioavailability after subcutaneous injection, a long half-life of 15--18 hours allowing for once daily administration, predictable anticoagulant effect with no requirement for monitoring, and no cross-reactivity with antibodies associated with HIT ([@b44]; [@b18]). Also, selective and potent targeting of an upstream step in the coagulation cascade theoretically achieves superior anticoagulation as inhibition of one molecule of factor Xa reduces the downstream production of many molecules of thrombin ([@b4]). [Table 2](#tbl2){ref-type="table"} summarizes the significant results from the 2 clinical end-point trials which investigate fondaparinux use in STEMI patients.

###### 

Clinical endpoint trials for the use of fondaparinux in STEMI patients

  Trial                                       Patients regimen                              Fondaparinux regimen                                                     UFH                                                                           Outcomes
  ------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PENTALYSE[a](#tf2-1){ref-type="table-fn"}   326 patients receiving fibrinolytic therapy   4 mg, 8 mg, or 12 mg, initial dose IV then SC once daily for 5--7 days   IV bolus, then infusion to maintain aPTT 50--75s for 48--72 hours             Fondaparinux as safe and effective as UFH in restoring coronary flow and preventing reocclusion.
  OASIS-6[b](#tf2-2){ref-type="table-fn"}     Stratum 1: 5658 patients                      2.5 mg SC once daily for up to 8 days                                    Placebo                                                                       Fondaparinux associated with a significant reduction in death or reinfarction compared with placebo.Fondaparinux associated with fewer major bleeds than placebo(non-significant).
                                              Stratum 2: 6434 patients                      2.5 mg IV bolus then 2.5 mg SC once daily for up to 8 days               IV bolus, then infusion to maintain aPTT 1.5--2 × normal for up to 48 hours   No significant difference in death or reinfarction between fondaparinux and UFH arms.No significant difference in bleeding.
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**Abbreviations:** UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.

The PENTALYSE study compared 5--7 days fondaparinux (4 mg, 8 mg, or 12 mg, initial dose IV then SC daily) with 48--72 hours UFH in 326 STEMI patients being treated with aspirin and alteplase ([@b15]). There was no difference in early artery patency determined by 90 minute coronary angiography. Patients who did not have coronary intervention during the treatment period, showed a trend to less reocclusion with fondaparinux (repeat angiography day 5--7). PENTALYSE reported a trend to increased instrumental bleeding but no overall increase in hemorrhage.

The large multi-centre OASIS 6 trial ([@b49]) is the first large scale trial to report on the efficacy and safety of fondaparinux in the setting of STEMI and therefore provides an extremely important extension of available evidence. It enrolled 12092 STEMI patients from 41 countries and randomized them in a complex design to fondaparinux (2.5 mg once daily for up to 8 days) or usual care which was defined as either placebo alone where UFH was not indicated (stratum 1, n = 5658), or UFH for up to 48 hours followed by placebo for up to 8 days in patients with an indication for UFH (stratum 2, n = 6434). The initial dose of fondaparinux was SC in stratum 1 and IV in stratum 2. The decision as to whether UFH was indicated was not predefined but based on the investigator's judgment. As with ExTRACT, it is important to note that stratum 2 was not only comparing 2 anticoagulants, but also 2 anticoagulation strategies. UFH was given for up to 48 hours only, while fondaparinux was given for up to 8 days. Fibrinolytic therapy was used in 45% of the patients (78.0% in stratum 1 and 15.9% in stratum 2), with streptokinase being the most commonly used (approximately 73%). Primary PCI was undertaken in 28.9% (0.2% in stratum 1 and 53.2% in stratum 2). Almost a quarter of patients (23.7%) did not receive any reperfusion therapy. The primary endpoint (death/re-MI) in stratum 1 patients was significantly reduced by fondaparinux compared with placebo (11.2 vs 14.0; HR 0.79 \[95% CI 0.68--0.92\]). This adds to existing evidence (from AMI-SK and CREATE trials) confirming adjuvant antithrombotic therapy is indicated along with fibrinolytic therapy, including streptokinase. In stratum 2 patients, there was no significant reduction in the primary endpoint for fondaparinux compared with UFH (8.3 vs 8.7; HR 0.96 \[95% CI 0.81--1.13\]). Also of note, in patients undergoing primary PCI there was an increase in complications with fondaparinux compared with UFH including guide catheter thrombosis, abrupt coronary artery closure, new angiographic thrombus, or no reflow. An interim protocol modification advising additional UFH in fondaparinux patients undergoing acute PCI was thus required.

Surprisingly, lower rates were observed for severe hemorrhage (44 vs 28; p = 0.06) and for major bleeds (57 vs 39; p = 0.07) with fondaparinux compared with placebo in stratum 1. This is in contrast to the CREATE trial which demonstrated a significant excess of life-threatening bleeding in patients who received reviparin compared to placebo. The reason for a reduction in major bleeding is not well understood -- some suggesting it may be a consequence of better clinical outcome and/or reduced need for urgent revascularization. In stratum 2, the rates of severe and major bleeds were similar in the 2 groups.

Several conclusions can be drawn from the OASIS-6 trial. There is clear benefit for fondaparinux in STEMI patients without an indication for UFH, where it is as safe as no anticoagulation. In conservatively managed STEMI patients with an indication for UFH who receive fibrinolytic therapy, fondaparinux is at least as effective and as safe as UFH. However, the use of fondaparinux as the sole anticoagulant for STEMI patients treated with primary PCI is associated with an increased risk of thrombotic complications, and thus pre-treatment with UFH before PCI is required.

Direct thrombin inhibitors
==========================

Unlike UFH, direct thrombin (factor IIa) inhibitors inactivate clot bound thrombin and prevent thrombin induced platelet aggregation. In the large GUSTO IIb trial ([@b33]) 2274 patients treated with fibrinolytic therapy for STEMI were randomly assigned to the direct thrombin inhibitor hirudin or UFH. In patients receiving streptokinase, hirudin compared with UFH was associated with a reduction in 30 day death/re-MI (8.6% vs 14.4%; p = 0.004) although no difference was seen in patients treated with tissue-type plasminogen activator (see [Table 3](#tbl3){ref-type="table"}). In the HIT 4 study ([@b35]), 1208 patients with STEMI were treated with aspirin and streptokinase and randomized to receive recombinant hirudin or heparin. A trend to earlier ST resolution was seen, but no difference in reinfarction, mortality or bleeding rates.

###### 

Evidence for direct thrombin inhibitors as adjuvant anticoagulation for patients with STEMI receiving fibrinolytic therapy

  Trial                                             Patients                                          DTI regimen                                                  UFH regimen                                                      Outcomes
  ------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GUSTO IIb trial[a](#tf3-1){ref-type="table-fn"}   2274 patients treated with fibrinolytic therapy   Hirudin IV infusion to maintain aPTT 60--85s for 3--5 days   IV bolus, then infusion to maintain aPTT 60--85s for 3--5 days   In patients receiving streptokinase, hirudin compared with UFH was associated with a reduction death or reinfarction.No significant difference in death or reinfarction for patients treated with tissue-type plasminogen activator.
  HIT 4[b](#tf3-2){ref-type="table-fn"}             1208 patients treated with streptokinase          Hirudin IV bolus followed by SC twice daily for 5--7 days    12500 U twice daily by SC injection                              No significant difference in death or reinfarction.No significant difference in bleeding.
  HERO[c](#tf3-3){ref-type="table-fn"}              412 patients treated with streptokinase           Bivalirudin IV bolus then infusion for 60 hours              IV bolus, then infusion for 60 hours                             No significant difference in death or reinfarction.Significant reduction in major bleeding with bivalirudin.
  HERO-2[d](#tf3-4){ref-type="table-fn"}            17073 patients treated with streptokinase         Bivalirudin IV bolus then infusion for 48 hours              IV bolus, then infusion to maintain aPTT 50--75s for 48 hours    No significant difference in 30 day mortality.Bivalirudin significantly reduced the rate of early (4 days) reinfarction.
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**Abbreviations:** UFH, unfractionated heparin; DTI, direct thrombin inhibitor; IV. intravenous; SC, subcutaneous.

A similar direct thrombin inhibitor, bivalirudin, showed improved early patency compared with UFH as an adjunct to streptokinase in the HERO study ([@b48]). In the large 17073 patient HERO-2 study, bivalirudin as an adjunct to streptokinase did not reduce mortality at 30 days compared with UFH, but did reduce the rate of re-infarction within 4 days by 30% ([@b47]). It is noteworthy that, unlike ExTRACT and OASIS-6, this trial compared identical treatment durations of the anticoagulants under investigation (48 hour infusion). The advantage of bivalirudin over UFH in terms of reduced reinfarction came at the cost of a relatively small increase in moderate bleeding (1.4% vs 1.1%; p = 0.05). There was no significant difference in the risk of severe bleeding. This finding of increased moderate bleeding is not consistent with previous trials ([@b31]). Again, more recently, bivalirudin has been associated with reduced bleeding compared with UFH plus antiplatelet glycoprotein IIb/IIIa inhibitors during early PCI for non-ST elevation acute coronary syndromes ([@b42]). It is currently being evaluated in the HORIZONS primary PCI STEMI trial, which is comparing bivalirudin to heparin plus glycoprotein IIb/IIIa inhibitor.

Summary and conclusions
=======================

The role of UFH in STEMI, particularly as an adjunct to fibrinolytic therapy, is being strongly challenged by the wealth of data surrounding newer anticoagulants including LMWH, factor Xa inhibitors and direct thrombin inhibitors. The evidence base is strongest for the LMWH enoxaparin where meta-analyses of multiple trials and the large ExTRACT trial have confirmed that enoxaparin (dose-adjusted for weight, renal function and age ≥75) compared with UFH, results in significant net clinical benefit. The recently published substudy of ExTRACT demonstrated superiority of enoxaparin over UFH in the patients who underwent PCI within 30 days of fibrinolytic therapy for STEMI, without a significant difference in bleeding. The results of this study also suggest that for patients commenced on adjuvant enoxaparin after fibrinolytic therapy there is no need to switch to UFH if they proceed to PCI during the period of anticoagulation. Thus while based on current evidence, enoxaparin may be considered the anticoagulant of choice in STEMI, the factor Xa inhibitor fondaparinux suggests the intriguing possibility of further reduction in bleeding risk without loss of efficacy. OASIS-6 has provided important data on 'real-world' use of fondaparinux, but because of the heterogeneous trial population and dependence on local investigator discretion to decide on the appropriateness of anticoagulant therapy, drawing firm conclusions for contemporary practice is difficult. Additionally, given the increasing provision of early PCI after successful fibrinolysis or rescue PCI after failed fibrinolytic therapy, the excess of guide catheter thrombosis is an apparent limitation. While the direct thrombin inhibitor bivalirudin was associated with increased bleeding compared with UFH in HERO-2, more recent trials have focused on its potential as a substitute for UFH plus IIbIIIa inhibitors (and hence potential for reduced bleeding) during PCI. The ongoing HORIZONS trial will provide important data regarding bivalirudin\'s role in primary PCI. However as most STEMI patients continue to receive a primary fibrinolytic strategy, a head-to-head comparison of fondaparinux and bivalirudin with dose adjusted enoxaparin in a clearly-defined, fibrinolytic-treated population is eagerly awaited.
